Characterization of exparel bupivacaine multivesicular liposomes.

Exparel is a bupivacaine multivesicular liposomes (MVLs) formulation developed based on the DepoFoam technology. The complex composition and the unique structure of MVLs pose challenges to the development and assessment of generic versions. In the present work, we developed a panel of analytical methods to characterize Exparel with respect to particle size, drug and lipid content, residual solvents, and pH. In addition, an accelerated in vitro drug release assay was developed using a rotator-facilitated, sample-and-separate experimental setup. The proposed method could achieve over 80% of bupivacaine release within 24 h, which could potentially be used for formulation comparison and quality control purposes. The batch-to-batch variability of Exparel was examined by the established analytical methods. Four different batches of Exparel showed good batch-to-batch consistency in drug content, particle size, pH, and in vitro drug release kinetics. However, slight variation in lipid contents were observed.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Anna Schwendeman reports financial support was provided by US Food and Drug Administration. Minzhi Yu reports financial support was provided by American Heart Association. Anna Schwendeman reports a relationship with EVOQ Therapeutics that includes: board membership, consulting or advisory, equity or stocks, and funding grants.
(Copyright © 2023 Elsevier B.V. All rights reserved.)